Suggested data for inclusion in future cases of reported TA-GVHD
| Data category . | Variables . |
|---|---|
| Clinical case and recipient | • Presence or absence of each of 7 clinical features listed in NHSN definition |
| • Timing of symptom onset relative to the implicated component (or, if uncertain, all transfusions) | |
| • Possible other causes of presentation | |
| • Medical history, including presence or absence of diagnoses indicating immunocompromise | |
| • Indication for, and circumstance of, transfusion | |
| • Parity (females) | |
| • Anti-HLA antibodies | |
| Product | • Components transfused, including number of units |
| • Product storage duration and conditions | |
| • Leukoreduction status (and technique of LR) | |
| • Irradiation status (and technique of irradiation, quality assurance measures) | |
| • Pathogen-reduced status (for platelets) | |
| • Donor (related, HLA-matched) | |
| Laboratory | • Biopsy of involved tissues or autopsy |
| • HLA typing of patient and product (or donor) ideally using molecular typing | |
| • Chimerism studies |
| Data category . | Variables . |
|---|---|
| Clinical case and recipient | • Presence or absence of each of 7 clinical features listed in NHSN definition |
| • Timing of symptom onset relative to the implicated component (or, if uncertain, all transfusions) | |
| • Possible other causes of presentation | |
| • Medical history, including presence or absence of diagnoses indicating immunocompromise | |
| • Indication for, and circumstance of, transfusion | |
| • Parity (females) | |
| • Anti-HLA antibodies | |
| Product | • Components transfused, including number of units |
| • Product storage duration and conditions | |
| • Leukoreduction status (and technique of LR) | |
| • Irradiation status (and technique of irradiation, quality assurance measures) | |
| • Pathogen-reduced status (for platelets) | |
| • Donor (related, HLA-matched) | |
| Laboratory | • Biopsy of involved tissues or autopsy |
| • HLA typing of patient and product (or donor) ideally using molecular typing | |
| • Chimerism studies |